To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics™ Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.
Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.
Dr. Paul Tumeh, a rising star in the field of cancer immunology, who focuses on the identification of immune cell-types that mediate tumor rejections during PD-1 by identifying niches (i.e., discrete cellular microenvironments) within tumors that drive or inhibit response to PD1/PDL1 blocking therapies. He is using PerkinElmer’s Phenoptics platform to develop biomarkers that could potentially stratify patients to subcategories of those likely to respond, those likely to respond after the immune system is activated to engage with the tumor (‘primed’), and those not likely to respond even after ‘priming.’